Summary Although small cell lung cancer (SCLC) is very chemosensitive, cerebral metastases are treated with radiotherapy in the belief that they are protected from chemotherapy by the blood-brain barrier (BBB). The validity of this assumption has not been tested in clinical practice. In a randomised trial of treatment in 610 patients with SCLC, 19 patients who had symptomatic cerebral metastases at presentation were treated initially with chemotherapy, and cranial irradiation withheld. (Long et al., 1979) . Indeed the increased permeability of tumour vessels to radiolabelled colloids and CT contrast media is fundamental to the radiological diagnosis of cerebral metastases. Despite this, when treating cerebral metastases it is often assumed that, because most cytotoxic drugs do not cross the intact BBB, chemotherapy will be ineffective.
Between 4 and 19% of patients with small cell lung cancer (SCLC) have cerebral metastases at presentation, and up to 30% develop clinically apparent brain metastases during the course of their illness (Nugent et al., 1979; Hirsch et al., 1983) . This relatively high incidence of cerebral metastases as a site of relapse has led to the brain being considered a (sanctuary site' for SCLC, protected from systemic chemotherapy by the blood-brain barrier (BBB) . In normal brain the BBB is maintained by tight connections between endothelial cells, but cerebral metastases derive their blood supply from new capillaries growing into the tumour (Folkman, 1976 ) which have endothelial fenestrations and gaps (Long et al., 1979) . Indeed the increased permeability of tumour vessels to radiolabelled colloids and CT contrast media is fundamental to the radiological diagnosis of cerebral metastases. Despite this, when treating cerebral metastases it is often assumed that, because most cytotoxic drugs do not cross the intact BBB, chemotherapy will be ineffective.
Even in SCLC, which is a highly chemosensitive tumour, chemotherapy has been largely ignored in the management of cerebral metastases, these patients being treated with steriods and cranial irradiation (Cox et al., 1980) . There are reports of radiologically proven responses of cerebral metastases to systemic chemotherapy in SCLC (Kantarjian et al., 1984; Postmus et al., 1987; Kristiansen & Hansen, 1988) but the response rate to a single regimen is not known. However, the only systematic study of conventional chemotherapy for cerebral metastases (Rosner et al., 1986) showed that cerebral metastases from breast cancer have the same frequency of response as secondary deposits at other sites.
Our aim was to assess in a prospective study the objective response rate of cerebral metastases in previously untreated SCLC patients who received uniform chemotherapy, rather than radiotherapy, as initial treatment.
Methods
Between February 1982 and September 1985, 610 patients with histologically or cytologically confirmed SCLC entered a multicentre randomised chemotherapy trial (Spiro et al., 1989 
Results
Twenty-five patients (4.1%) had symptomatic cerebal metastases at presentation. Six patients were excluded from the analysis of response to chemotherapy, four who were initially treated with cranial irradiation before being referred to the study centre, and two who underwent craniotomy before chemotherapy. The effect of chemotherapy on cerebral metastases could be assessed in the remaining 19 evaluable patients whose characteristics on entry to the study are b shown in Table I .
Response to chemotherapy
All 19 evaluable patients had a CT or isotope scan before chemotherapy. In 14/19 patients a second brain scan was obtained after chemotherapy. In these 14 radiologically assessable patients, nine had responded after four cycles of chemotherapy. Of these, eight had a partial response assessed by CT scanning and one a complete response on repeat isotope brain scan. The remaining five radiologically assessable patients were non-responders. An additional CT scan was obtained after a single cycle of treatment in nine of the 14 radiologically assessable patients. Of these, five showed a response at this early stage. All nine patients with radiologically proven response also had improvement of their neurological function.
Five of 19 patients did not have a second scan. Four of these had rapid deterioration in neurological state, and progression of disease at other sites. The remaining patient had a clear improvement in neurological state with complete resolution of ataxia and headaches. This patient is considered as a clinical responder.
The overall response was therefore 10/19 (53%). Only three of the 10 responders (nine radiological, one clinical) were given steroids and these were discontinued before response was assessed. The response of the intrathoracic tumour was 15/19 (79%). The five patients who responded in the chest but not in the brain were not clinically distinguishable from the patients who responded at both sites. Figure 1 shows a series of enhanced CT brain scans from a man with SCLC who presented with headache and left-sided weakness. A large right frontal metastasis, and a smaller left parietal lesion were present before chemotherapy. Both were markedly smaller following the first cycle of chemotherapy and after four cycles of chemotherapy only a frontal low density area, with no enhancement, remained. His (Spiro, 1985) . Cerebral metastases are regarded as an exception to this rule, conventional treatment being with radiotherapy in the belief that such metastases are protected from systemic chemotherapy by the BBB. Undoubtedly tight capillary endothelial junctions do maintain the BBB in normal brain (Brightman & Reese, 1969) , but increased tumour vessel permeability is the basis for diagnosing cerebral metastases by radionucleide brain scan or enhanced CT scan. Tumours produce angiogenic factors (Folkman, 1976) and derive their blood supply from new vessels growing into the tumour. Endothelial gaps are present in the tumour vessels (Long, 1979) , implying that cerebral metastases do not lie beyond the BBB.
The prognosis for SCLC patients with cerebral metastases who are treated by cranial irradiation is poor, and many have a dismal quality of life (Felletti et al., 1985; Lucas et al., 1986 ). The brain is rarely the sole site of metastasis in SCLC (Nugent et al., 1979) , and patients receiving cranial irradiation alone often die of extra-cranial tumour rather than cerebral metastases (Cairncross et al., 1980) . Nevertheless, there are only a few reports of SCLC cerebral metastases responding to conventional chemotherapy (Kantarjian et al., 1984; Kristjansen & Hansen, 1988) , and a single study of treatment with high-dose chemotherapy (Postmus et al., 1987) . The question we have asked is how often do SCLC cerebral metastases respond to a single conventional chemotherapy regimen, used in place of radiotherapy as initial treatment. We have studied untreated patients with SCLC and symptomatic cerebral metastases at presentation who received uniform chemotherapy with response assessed objectively by serial CT or radionucleide brain scans.
The response rate for cerebral metastases in these patients treated with conventional combination chemotherapy alone was 53%. In a recent study of SCLC patients with brain metastases, Kristjansen & Hansen (1988) reported responses to chemotherapy in all seven evaluable patients. However, a variety of chemotherapy regimens were used, and all patients initially received high dose steriods. Postmus et al. (1987) demonstrated responses in four of nine evaluable SCLC patients with cerebral metastases given high dose etoposide to overcome the BBB which is normally impermeable to etoposide (Creave, 1982) . In contrast to the present study, many of their patients had relapsed after cranial irradiation or received previous chemotherapy, and the toxicity of highdose etoposide was considerable. Our results in a larger, well-defined, group receiving uniform, conventional chemotherapy provide a clear indication of the responsiveness of SCLC cerebral metastases. It is possible that the response rate for cerebral metastases is lower than for the primary tumour. However, the numbers of patients studied are small and there are technical difficulties in assessing the response of intracranial tumours to treatment. By combining the results of CT and radionuclide brain scans with neurological examination a relatively accurate assessment of response can be achieved (Levin et al., 1977) . The distinction between CR and PR remains difficult because damage to neurological tissues may persist despite successful treatment. The difference in response rate between the brain and primary tumour may, however, be genuine. Studies of experimental brain tumours in animals have shown that the BBB may be preserved in very small metastases and also at the margins of larger deposits (Hasegawa et al., 1983) . The relationship between cerebral metastases, the vascular endothelium and drug delivery is therefore complex (Greig, 1987) .
None of the drugs used in this study crosses the BBB easily in normal brain (Workman, 1986) . The present study, and that of Rosner et al. (1986) in breast cancer, which show response rates in the brain similar to those at other sites of metastatic disease, suggest the hypothesis that the BBB is not the most important consideration in treating cerebral metastases. Indeed, the term BBB is a misnomer in cerebral metastases: blood-tumour barrier is a more appropriate description.
To be useful in clinical practice, responses to chemotherapy must be rapid, accompanied by clinical improvement, and sustained. In our study, CT scans repeated after just one cycle of chemotherapy showed a definite response, which was accompanied by improvement of neurological signs. We cannot comment directly on response duration because the study design included the option of cranial irradiation for patients who had responded to chemotherapy. The policy of chemotherapy as initial treatment for brain metastases has not been compared with initial radiotherapy in a randomised trial, but we have not found evidence of a detriment in survival (Cox et al., 1980; Giannone et al., 1987) .
The place of chemotherapy in treating patients with cerebral metastases in this and other cancers will be determined by the chemosensitivity of the primary tumour, the presence of extracranial disease and the effectiveness of conventional treatment with cranial irradiation. In chemosensitive tumours such as SCLC, where the treatment is palliative and extracranial disease almost invariably present, initial treatment with chemotherapy may have several advantages over cranial irradiation. Chemotherapy may start immediately and simultaneously treats both cerebral metastases and other sites of disease. This is important because many patients treated by cranial radiotherapy alone die of extracranial tumour. These patients may be spared the need for additional treatment with cranial irradiation requiring daily travel or admission to hospital. Finally, we have shown that after the first cycle of chemotherapy, response can be assessed by CT scan and clinical examination. If there has been no response, the chemotherapy can be discontinued and the patient may then be treated with cranial irradiation. Such a policy carries the advantages of initial treatment to all sites of disease, both primary and metastatic, with early addition of cranial irradiation for patients in whom this is clearly necessary. This work was supported by a grant from the Cancer Research Campaign.
